Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Increase in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totaling 144,231 shares, a growth of 14,572.5% from the April 15th total of 983 shares. Based on an average trading volume of 357,947 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the shares of the company are sold short.

Fresenius SE & Co. Stock Performance

Shares of FSNUY opened at $11.74 on Wednesday. The company has a 50-day simple moving average of $12.87 and a 200-day simple moving average of $14.09. The company has a quick ratio of 1.00, a current ratio of 1.32 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $26.45 billion, a PE ratio of 15.65 and a beta of 0.68. Fresenius SE & Co. has a 52-week low of $11.28 and a 52-week high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.29%. The company had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $6.79 billion. Equities research analysts predict that Fresenius SE & Co. will post 1.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on FSNUY. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, April 20th. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a report on Tuesday, February 3rd. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.